How are NovaBridge Biosciences (NBP) American Depositary Shares related to Ordinary Shares?

Footnotes state that each 10 American Depositary Shares represent 23 Ordinary Shares of NovaBridge Biosciences. This ratio explains how ADS prices and counts translate into the underlying Ordinary Shares when the company or insiders report holdings and transactions in both forms.

NovaBridge CMO sells shares, exercises RSUs

NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew reported a combination of option activity and share sales.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew reported a combination of option activity and share sales. He sold 8,494 Ordinary Shares in an open-market sale at $0.66 per share and, the prior day, exercised derivative awards into 10,302 Ordinary Shares represented by American Depositary Shares (ADSs). Following these transactions, he directly held 157,941 Ordinary Shares and 82,422 Restricted Share Units (RSUs), which each represent a right to receive one ADS.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Dennis Phillip Andrew

Role Chief Medical Officer

Sold 8,494 shs ($6K)

Approx. gross sale proceeds $6K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	8,494	$0.66	$6K
Exercise	Restricted Share Units	10,302	$0.00	$0.00
Exercise	Ordinary Shares	23,695	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 82,422 contracts (Direct); Ordinary Shares — 157,941 shares (Direct)

Footnotes (9)

F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2. Reported securities are represented by 10,302 ADSs.
F3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
F4. Reported securities are represented by 72,363 ADSs.
F5. Reported securities are represented by 3,693 ADSs.
F6. Reported sales price represents the converted sales price of the ADSs of $1.51.
F7. Reported securities are represented by 68,670 ADSs.
F8. Reported securities represent ADSs.
F9. On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month.

Key Figures

Ordinary Shares sold: 8,494 shares Sale price per Ordinary Share: $0.66 per share ADS sale price: $1.51 per ADS +4 more

7 metrics

Ordinary Shares sold 8,494 shares Open-market sale on 2026-06-18

Sale price per Ordinary Share $0.66 per share Converted from ADS sales price

ADS sale price $1.51 per ADS Footnote F6 converted sales price

RSUs exercised 10,302 units Converted into Ordinary Shares on 2026-06-17

Ordinary Shares after transactions 157,941 shares Direct ownership following sale

RSUs remaining 82,422 units Direct RSU holdings after exercise

RSU grant size 164,840 RSUs Granted on 2024-06-17, vesting over four years

Key Terms

American Depositary Shares, Restricted Share Units, RSU, open-market sale, +1 more

5 terms

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares ("ADS")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

RSU financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one ADS."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

open-market sale financial

"transaction_action: "open-market sale" for 8,494 Ordinary Shares."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for RSUs into Ordinary Shares."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NovaBridge Biosciences (NBP) report for its CMO?

NovaBridge Biosciences’ Chief Medical Officer reported an open-market sale and RSU exercises. He sold 8,494 Ordinary Shares at $0.66 per share and exercised derivative awards into 10,302 Ordinary Shares represented by ADSs, while retaining a sizeable equity position afterward.

How many NovaBridge Biosciences (NBP) shares did the CMO sell and at what price?

The CMO sold 8,494 Ordinary Shares of NovaBridge Biosciences at $0.66 per share. A footnote explains this reflects a converted ADS sales price of $1.51, because the company’s Ordinary Shares may also trade as American Depositary Shares in the market.

What derivative or RSU activity did the NovaBridge Biosciences (NBP) CMO report?

He exercised derivative securities described as Restricted Share Units, converting 10,302 RSUs into an equivalent number of Ordinary Shares represented by ADSs. Each RSU corresponds to one ADS, giving him actual share ownership instead of contingent rights once the units vest and convert.

What are the CMO’s NovaBridge Biosciences (NBP) holdings after these transactions?

After the reported transactions, the CMO directly held 157,941 Ordinary Shares and 82,422 Restricted Share Units. These RSUs represent contingent rights to receive ADSs as they vest under the award terms, supplementing his existing Ordinary Share ownership stake in the company.

What RSU grant terms apply to the NovaBridge Biosciences (NBP) CMO?

On June 17, 2024, the CMO was granted 164,840 RSUs. One quarter vests on the first anniversary of the grant date, with the remaining three quarters vesting in equal installments over the subsequent 12 quarters, on the 17th day of every third month.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 05:23 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dennis Phillip Andrew

(Last)

(First)

(Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	06/17/2026		M		23,695⁽²⁾	A	⁽³⁾	166,435⁽⁴⁾	D
Ordinary Shares⁽¹⁾	06/18/2026		S		8,494⁽⁵⁾	D	$0.66⁽⁶⁾	157,941⁽⁷⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽³⁾	06/17/2026		M			10,302⁽⁸⁾	⁽⁹⁾	⁽⁹⁾	Ordinary Shares⁽¹⁾	10,302⁽⁸⁾	$0	82,422⁽⁸⁾	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 10,302 ADSs.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

4. Reported securities are represented by 72,363 ADSs.

5. Reported securities are represented by 3,693 ADSs.

6. Reported sales price represents the converted sales price of the ADSs of $1.51.

7. Reported securities are represented by 68,670 ADSs.

8. Reported securities represent ADSs.

9. On June 17, 2024, the Reporting Person was granted 164,840 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month.

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR